Eupraxia Pharmaceuticals Appoints Three Directors as EP-104GI Approaches Late-Stage Milestones

With EP-104GI advancing toward late-stage milestones, Eupraxia Pharmaceuticals has expanded its board with three appointments carrying deep commercialization and clinical development credentials, a signal that the Vancouver-based biotech is structuring governance ahead of a potential regulatory pathway rather than after it.

Robert Bazemore, Amy Pott, and Dr. Helen Thackray join the board effective immediately, replacing outgoing directors Paul Geyer and Michael Wilmink. Bazemore brings more than 30 years of drug development and launch experience, including the commercialization of TAZVERIK® at Epizyme and US launches of ZYTIGA® and IBRUTINIB at Janssen Biotech under Johnson & Johnson. His tenure at Merck & Co. included support for the SINGULAIR® US launch. He currently holds independent director roles at Nuvation Bio and Ardelyx.

Pott's profile is weighted toward commercial operations in rare disease and gene therapy. She currently serves as Global Chief Commercialization Officer at enGene, following senior commercial roles at Astellas Pharma covering gene therapies and ophthalmic rare diseases, and prior positions at Swedish Orphan Biovitrum and Shire. For a company whose Diffusphere™ platform targets controlled local drug delivery in gastroenterology, her experience building commercial infrastructure in specialty and rare disease categories is directly relevant.

Dr. Thackray contributes more than 25 years of biotech leadership spanning preclinical-stage companies through mature public enterprises with approved products and market capitalizations above $2 billion. The breadth of that experience across development stages positions her to support Eupraxia's pipeline expansion beyond EP-104GI.

CEO Dr. James Helliwell cited the collective expertise in late-stage development, commercial strategy, and global product launches as aligned with upcoming milestones for EP-104GI and broader gastroenterology pipeline activity. The board restructuring coincides with a period in which clinical-stage biotechs are increasingly front-loading commercialization expertise at the governance level, rather than recruiting it post-approval.

The measurable test of this board composition will arrive when Eupraxia publishes its next EP-104GI data readout and the commercial planning assumptions behind it come under investor and regulatory scrutiny.

Source: Eupraxia Pharmaceuticals via GlobeNewswire, July 7, 2026.